The "science behind the FDA's decisions on what cancer studies can be introduced to the public is in the politics, and the fact that Pharma feeds the FDA's pockets, through direct fees drug companies pay the FDA to get their products reviewed, and the less-reportable, more lucrative bonuses drug companies give the FDA for such things as travel expenses and speakers' fees.